E
BioNxt Solutions Inc.
BNXT
CNSX
E
Sell
7/22/2024Downgrade
BioNxt Solutions Inc. (BNXT) was downgraded to E+ from D- on 7/22/2024 due to a decline in the volatility index and total return index.
BioNxt Solutions Inc. (BNXT) was downgraded to E+ from D- on 7/22/2024 due to a decline in the volatility index and total return index.
D
Sell
7/5/2024Upgraded
BioNxt Solutions Inc. (BNXT) was upgraded to D- from E+ on 7/5/2024 due to an increase in the volatility index and valuation index.
BioNxt Solutions Inc. (BNXT) was upgraded to D- from E+ on 7/5/2024 due to an increase in the volatility index and valuation index.
E
Sell
6/13/2024Downgrade
BioNxt Solutions Inc. (BNXT) was downgraded to E+ from D- on 6/13/2024 due to a decline in the solvency index, volatility index and total return index. The quick ratio declined from 0.1 to 0.03, and debt to equity increased from -0.9 to -0.84.
BioNxt Solutions Inc. (BNXT) was downgraded to E+ from D- on 6/13/2024 due to a decline in the solvency index, volatility index and total return index. The quick ratio declined from 0.1 to 0.03, and debt to equity increased from -0.9 to -0.84.
D
Sell
6/5/2024Upgraded
BioNxt Solutions Inc. (BNXT) was upgraded to D- from E+ on 6/5/2024 due to an increase in the volatility index and valuation index.
BioNxt Solutions Inc. (BNXT) was upgraded to D- from E+ on 6/5/2024 due to an increase in the volatility index and valuation index.
E
Sell
5/17/2024Downgrade
BioNxt Solutions Inc. (BNXT) was downgraded to E+ from D- on 5/17/2024 due to a decline in the growth index, total return index and volatility index. EBIT declined 79.74% from -$805.1 to -$1.45M, earnings per share declined from -$0.0106 to -$0.0172, and operating cash flow declined 18.54% from -$803.8 to -$952.8.
BioNxt Solutions Inc. (BNXT) was downgraded to E+ from D- on 5/17/2024 due to a decline in the growth index, total return index and volatility index. EBIT declined 79.74% from -$805.1 to -$1.45M, earnings per share declined from -$0.0106 to -$0.0172, and operating cash flow declined 18.54% from -$803.8 to -$952.8.
D
Sell
1/24/2024Upgraded
BioNxt Solutions Inc. (BNXT) was upgraded to D- from E+ on 1/24/2024 due to a noticeable increase in the total return index and volatility index.
BioNxt Solutions Inc. (BNXT) was upgraded to D- from E+ on 1/24/2024 due to a noticeable increase in the total return index and volatility index.
E
Sell
1/4/2024Downgrade
BioNxt Solutions Inc. (BNXT) was downgraded to E+ from D- on 1/4/2024 due to a decline in the volatility index.
BioNxt Solutions Inc. (BNXT) was downgraded to E+ from D- on 1/4/2024 due to a decline in the volatility index.
D
Sell
12/15/2023Upgraded
BioNxt Solutions Inc. (BNXT) was upgraded to D- from E+ on 12/15/2023 due to a major increase in the growth index, volatility index and valuation index. EBIT increased 45.95% from -$1.49M to -$805.1, earnings per share increased from -$0.0178 to -$0.0106, and operating cash flow increased 10.6% from -$899.1 to -$803.8.
BioNxt Solutions Inc. (BNXT) was upgraded to D- from E+ on 12/15/2023 due to a major increase in the growth index, volatility index and valuation index. EBIT increased 45.95% from -$1.49M to -$805.1, earnings per share increased from -$0.0178 to -$0.0106, and operating cash flow increased 10.6% from -$899.1 to -$803.8.
E
Sell
5/9/2023Downgrade
BioNxt Solutions Inc. (BNXT) was downgraded to E+ from D- on 5/9/2023 due to a decline in the volatility index.
BioNxt Solutions Inc. (BNXT) was downgraded to E+ from D- on 5/9/2023 due to a decline in the volatility index.
D
Sell
4/21/2023Upgraded
BioNxt Solutions Inc. (BNXT) was upgraded to D- from E+ on 4/21/2023 due to an increase in the valuation index, volatility index and total return index.
BioNxt Solutions Inc. (BNXT) was upgraded to D- from E+ on 4/21/2023 due to an increase in the valuation index, volatility index and total return index.
E
Sell
3/14/2023Downgrade
BioNxt Solutions Inc. (BNXT) was downgraded to E+ from D on 3/14/2023 due to a decline in the valuation index.
BioNxt Solutions Inc. (BNXT) was downgraded to E+ from D on 3/14/2023 due to a decline in the valuation index.
D
Sell
2/9/2023Upgraded
BioNxt Solutions Inc. (BNXT) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
BioNxt Solutions Inc. (BNXT) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
E
Sell
2/8/2023Downgrade
BioNxt Solutions Inc. (BNXT) was downgraded to E+ from D on 2/8/2023 due to a large decline in the solvency index, total return index and volatility index.
BioNxt Solutions Inc. (BNXT) was downgraded to E+ from D on 2/8/2023 due to a large decline in the solvency index, total return index and volatility index.
D
Sell
5/16/2022Upgraded
BioNxt Solutions Inc. (BNXT) was upgraded to D from E+ on 05/16/2022.
BioNxt Solutions Inc. (BNXT) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
XPhyto Therapeutics Corp. (XPHY) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
XPhyto Therapeutics Corp. (XPHY) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
D
Sell
5/4/2022Upgraded
BioNxt Solutions Inc. (BNXT) was upgraded to D from E+ on 05/04/2022.
BioNxt Solutions Inc. (BNXT) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
XPhyto Therapeutics Corp. (XPHY) was downgraded to E+ from D on 5/1/2022 due to a major decline in the solvency index, growth index and valuation index. Debt to equity increased from 0.77 to 2.88, earnings per share declined from -$0.0285 to -$0.09, and EBIT declined 99.36% from -$1.88M to -$3.74M.
XPhyto Therapeutics Corp. (XPHY) was downgraded to E+ from D on 5/1/2022 due to a major decline in the solvency index, growth index and valuation index. Debt to equity increased from 0.77 to 2.88, earnings per share declined from -$0.0285 to -$0.09, and EBIT declined 99.36% from -$1.88M to -$3.74M.
D
Sell
4/21/2022Upgraded
XPhyto Therapeutics Corp. (XPHY) was upgraded to D from E+ on 4/21/2022 due to an increase in the total return index.
XPhyto Therapeutics Corp. (XPHY) was upgraded to D from E+ on 4/21/2022 due to an increase in the total return index.
E
Sell
4/20/2022Downgrade
XPhyto Therapeutics Corp. (XPHY) was downgraded to E+ from D on 4/20/2022 due to a noticeable decline in the total return index.
XPhyto Therapeutics Corp. (XPHY) was downgraded to E+ from D on 4/20/2022 due to a noticeable decline in the total return index.
D
Sell
11/9/2021Upgraded
BioNxt Solutions Inc. (BNXT) was upgraded to D from E+ on 11/09/2021.
BioNxt Solutions Inc. (BNXT) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
XPhyto Therapeutics Corp. (XPHY) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index and solvency index. The quick ratio declined from 3.53 to 1.69, and debt to equity increased from 0.5 to 0.74.
XPhyto Therapeutics Corp. (XPHY) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index and solvency index. The quick ratio declined from 3.53 to 1.69, and debt to equity increased from 0.5 to 0.74.
D
Sell
9/1/2020Upgraded
XPhyto Therapeutics Corp. (XPHY) was upgraded to D from D- on 9/1/2020 due to an increase in the solvency index and valuation index. Debt to equity declined from 0.27 to 0.08.
XPhyto Therapeutics Corp. (XPHY) was upgraded to D from D- on 9/1/2020 due to an increase in the solvency index and valuation index. Debt to equity declined from 0.27 to 0.08.
D
Sell
5/1/2020Upgraded
XPhyto Therapeutics Corp. (XPHY) was upgraded to D- from E on 5/1/2020 due to a noticeable increase in the growth index and total return index. Total revenue increased 262.17% from $34.1 to $123.5, EBIT increased 53.58% from -$2.82M to -$1.31M, and earnings per share increased from -$0.0596 to -$0.0336.
XPhyto Therapeutics Corp. (XPHY) was upgraded to D- from E on 5/1/2020 due to a noticeable increase in the growth index and total return index. Total revenue increased 262.17% from $34.1 to $123.5, EBIT increased 53.58% from -$2.82M to -$1.31M, and earnings per share increased from -$0.0596 to -$0.0336.
E
Sell
2/4/2020Upgraded
XPhyto Therapeutics Corp. (XPHY) was upgraded to E from E- on 2/4/2020 due to a large increase in the solvency index, total return index and volatility index.
XPhyto Therapeutics Corp. (XPHY) was upgraded to E from E- on 2/4/2020 due to a large increase in the solvency index, total return index and volatility index.
E
Sell
10/29/2019None
BioNxt Solutions Inc. (BNXT) was downgraded to E- from U on 10/29/2019.
BioNxt Solutions Inc. (BNXT) was downgraded to E- from U on 10/29/2019.
